文献速递妇科

一项多中心、开放标签、扩展性2期研究:评估伊立替康聚合物偶联物依替立康 pegol 在铂类耐药或难治性复发性卵巢癌女性中的安全性与疗效

A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2017-09-19

这项多中心、开放标签、扩展性2期研究评估了依替立康 pegol(EP)每21天给药一次在铂类耐药卵巢癌(PROC)患者中的疗效与安全性。139例入组,可评估的mITT组132例客观缓解率(ORR)为15.2%(95%CI 9.5-22.4),中位无进展生存期(PFS)4.4个月、总生存期(OS)10.2个月;既往接受过聚乙二醇脂质体多柔比星(PLD)的pEFF组104例ORR为14.4%(95%CI 8.3-22.7)。研究确认单药EP在PROC中具有活性和安全性,作者认为值得在疾病更早期及联合治疗中进一步评估。

要点

  • mITT组132例ORR为15.2%(95%CI 9.5-22.4),中位PFS 4.4个月、OS 10.2个月。
  • 既往接受PLD的pEFF组104例ORR为14.4%(95%CI 8.3-22.7),中位PFS 4.4个月、OS 10.9个月。
  • 最常见3/4级毒性为腹泻20%、腹痛17%、呕吐14%、脱水13%、恶心13%。

核心结论

  • 本研究确认单药依替立康 pegol 在铂类耐药卵巢癌患者中具有活性和安全性,包括既往接受过聚乙二醇脂质体多柔比星的患者。
  • 作者认为值得在疾病更早期及联合治疗中进一步评估。

研究设计与样本

  • 多中心、开放标签、2期扩展研究,评估依替立康 pegol 每21天给药一次用于铂类耐药卵巢癌。
  • 共入组139例患者;改良意向治疗(mITT)组132例,为至少接受一剂且有可测量病灶者;主要疗效(pEFF)组104例,为mITT中既往接受过聚乙二醇脂质体多柔比星者。
  • 主要终点为按实体瘤疗效评价标准1.0版评估的客观缓解率(ORR);次要终点包括无进展生存期(PFS)、总生存期(OS)和安全性。

主要发现

  • mITT组132例中20例达到ORR,为15.2%(95%CI 9.5-22.4);中位PFS 4.4个月,中位OS 10.2个月。
  • pEFF组104例中15例达到ORR,为14.4%(95%CI 8.3-22.7);中位PFS 4.4个月,中位OS 10.9个月。
  • 最常见的3/4级毒性为腹泻(20%)、腹痛(17%)、呕吐(14%)、脱水(13%)和恶心(13%)。
  • 严格遵循筛查和管理指南后,严重腹泻降至15%。

局限性

  • 作者在结论中提出需在疾病更早期及联合治疗中进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Etirinotecan pegol (EP) is a novel polyethylene glycol conjugated form of irinotecan with documented activity in platinum-resistant ovarian cancer (PROC). We report the results of the expanded portion of a phase II study of EP in patients with PROC who received prior pegylated liposomal doxorubicin (PLD) or who were unable to receive it. METHODS: This multicenter, open-label, phase II study evaluated EP q21d for PROC. The primary endpoint was objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors version 1.0. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety. Patient populations evaluated included a modified intent-to-treat (mITT) group consisting of all patients who received at least one dose and with measurable disease and a primary efficacy (pEFF) group (subset of the mITT population who received prior PLD). RESULTS: One hundred thirty-nine patients were enrolled. Of the 132 patients in the mITT group, 20 achieved an ORR (15.2%; 95% CI 9.5-22.4); median PFS and OS were 4.4 months and 10.2 months, respectively. In the pEFF group (n=104), 15 patients (14.4%; 95% CI 8.3-22.7) achieved an ORR; median PFS and OS were 4.4 months and 10.9 months, respectively. The most common grade 3/4 toxicities were diarrhea (20%), abdominal pain (17%), vomiting (14%), dehydration (13%), and nausea (13%). Severe diarrhea was reduced to 15% with strict adherence to screening and management guidelines. CONCLUSIONS: This study confirms the activity and safety of single-agent EP in patients with PROC, including patients who received prior PLD. Further evaluation earlier in the disease course and in combination is warranted.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Rustin G, Vergote I, Micha JP, et al. A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer. Gynecol Oncol. 2017. PMID: 28935273. doi:10.1016/j.ygyno.2017.08.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。